A phase I dose-escalation study of TAS-102 in patients (pts) with refractory metastatic colorectal cancer (mCRC).
Manish R. Patel
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose
Robert J. Mayer
No relevant relationships to disclose
Fabio M. Benedetti
Employment or Leadership Position - Taiho Pharmaceutical
Lee S. Rosen
Research Funding - Taiho Pharmaceutical